Abstract：Objective The aim of this report is to explore the effects of atorvastatin calcium tablets combined with sacubitril/valsartan on clinical efficacy, cardiac color ultrasound indexes and serum indexes in patients with chronic heart failure. Methods We collected data of 87 patients with chronic heart failure admitted to Sanzhen Rehabilitation Hospital in Changsha, Hunan Province from January 2022 to December 2022. According to the random number table method, the patients were divided into control group (treated with atorvastatin calcium tablets orally and diuretics, etc. ) with 43 cases and observation group (treated with sacubitril/valsartan plus the same therapy as the control group) with 44 cases. Results were compared between the two groups, including post-therapy efficacy and readmission rates, cardiac ultrasound and serum indexes before and after treatment, and the occurrence of adverse reactions during treatment. Results After 2 months of treatment, the total clinical efficiency of the observation group was 95.45%, which was significantly higher than that of the control group (74.42%). And the overall incidence of adverse reactions and the readmission rate of the observation group were observably lower than those of the control group. Compared with the pre-therapy period, an increase of various indicators was significantly obvious in both groups after treatment, including left ventricular ejection fraction (LVEF), systolic peak velocity (SPV), left anterior descending branch diastolic peak velocity (DPV) and time velocity integral (TVI). And the changes in the observation group were signally more obvious than the control group, with statistically significant differences between the two groups. Both of the two groups had an evident decrease in the left ventricular end-systolic diameter (LVESD) and the left ventricular end-diastolic diameter (LVEDD). And the LVESD and LVEDD were lower in the observation group than in the control group. However, there was no statistically significant difference in LVEDD level through the intra-group comparison of the control group before and after treatment. Conclusion Atorvastatin calcium tablets combined with sacubitril/valsartan has a good application effect in patients with chronic heart failure, as it apparently contributes to improving the prognosis and enhancing the quality of their lives.
2023, Vol. 20 
